Clinical and Experimental Reproductive Medicine

The Korean Society for Reproductive Medicine (대한생식의학회)
권호 표지
DOI QR코드

DOI QR Code

Expression of the genes for peroxisome proliferator-activated receptor-γ, cyclooxygenase-2, and proinflammatory cytokines in granulosa cells from women with polycystic ovary syndrome

  • Received : 2017.03.10
  • Accepted : 2017.06.19
  • Published : 2017.09.26
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: To identify differences in the expression of the genes for peroxisome proliferator-activated receptor $(PPAR)-{\gamma}$, cyclooxygenase (COX)-2, and the proinflammatory cytokines interleukin (IL)-6 and tumor necrosis factor $(TNF)-{\alpha}$ in granulosa cells (GCs) from polycystic ovary syndrome (PCOS) patients and controls undergoing controlled ovarian stimulation. Methods: Nine patients with PCOS and six controls were enrolled in this study. On the day of oocyte retrieval, GCs were collected from pooled follicular fluid. Total mRNA was extracted from GCs. Reverse transcription was performed and gene expression levels were quantified by realtime quantitative polymerase chain reaction. Results: There were no significant differences in age, body mass index, and total gonadotropin dose, except for the ratio of luteinizing hormone to follicle-stimulating hormone between the PCOS and control groups. $PPAR-{\gamma}$ and COX-2 mRNA was significantly downregulated in the GCs of PCOS women compared with controls (p= 0.034 and p= 0.018, respectively), but the expression of IL-6 and $TNF-{\alpha}$ mRNA did not show significant differences. No significant correlation was detected between the expression of these mRNA sequences and clinical characteristics, including the number of retrieved oocytes, oocyte maturity, cleavage, or the good embryo rate. Positive correlations were found among the $PPAR-{\gamma}$, COX-2, IL-6, and $TNF-{\alpha}$ mRNA levels. Conclusion: Our data may provide novel clues regarding ovarian GC dysfunction in PCOS, and indirectly provide evidence that the effect of $PPAR-{\gamma}$ agonists in PCOS might result from alterations in the ovarian follicular environment. Further studies with a larger sample size are required to confirm these proposals.

Keywords

References

  1. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352:1223-36. https://doi.org/10.1056/NEJMra041536
  2. Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007;356:551-66. https://doi.org/10.1056/NEJMoa063971
  3. Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome. Hum Reprod Update 2008;14:367-78. https://doi.org/10.1093/humupd/dmn015
  4. Swain JE, Pool TB. ART failure: oocyte contributions to unsuccessful fertilization. Hum Reprod Update 2008;14:431-46. https://doi.org/10.1093/humupd/dmn025
  5. Kenigsberg S, Bentov Y, Chalifa-Caspi V, Potashnik G, Ofir R, Birk OS. Gene expression microarray profiles of cumulus cells in lean and overweight-obese polycystic ovary syndrome patients. Mol Hum Reprod 2009;15:89-103.
  6. Kang S, Tsai LT, Rosen ED. Nuclear mechanisms of insulin resistance. Trends Cell Biol 2016;26:341-51. https://doi.org/10.1016/j.tcb.2016.01.002
  7. Froment P, Gizard F, Defever D, Staels B, Dupont J, Monget P. Peroxisome proliferator-activated receptors in reproductive tissues: from gametogenesis to parturition. J Endocrinol 2006;189:199-209. https://doi.org/10.1677/joe.1.06667
  8. Huang Z, Zhou X, Nicholson AC, Gotto AM Jr, Hajjar DP, Han J. Activation of peroxisome proliferator-activated receptor-alpha in mice induces expression of the hepatic low-density lipoprotein receptor. Br J Pharmacol 2008;155:596-605.
  9. Komar CM. Peroxisome proliferator-activated receptors (PPARs) and ovarian function: implications for regulating steroidogenesis, differentiation, and tissue remodeling. Reprod Biol Endocrinol 2005;3:41. https://doi.org/10.1186/1477-7827-3-41
  10. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18. https://doi.org/10.1056/NEJMra041001
  11. Qu F, Wang FF, Yin R, Ding GL, El-Prince M, Gao Q, et al. A molecular mechanism underlying ovarian dysfunction of polycystic ovary syndrome: hyperandrogenism induces epigenetic alterations in the granulosa cells. J Mol Med (Berl) 2012;90:911-23. https://doi.org/10.1007/s00109-012-0881-4
  12. Minge CE, Ryan NK, Van Der Hoek KH, Robker RL, Norman RJ. Troglitazone regulates peroxisome proliferator-activated receptors and inducible nitric oxide synthase in murine ovarian macrophages. Biol Reprod 2006;74:153-60. https://doi.org/10.1095/biolreprod.105.043729
  13. Vural P, Degirmencioglu S, Saral NY, Akgul C. Tumor necrosis factor alpha (-308), interleukin-6 (-174) and interleukin-10 (-1082) gene polymorphisms in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2010;150:61-5. https://doi.org/10.1016/j.ejogrb.2010.02.010
  14. Amalfi S, Velez LM, Heber MF, Vighi S, Ferreira SR, Orozco AV, et al. Prenatal hyperandrogenization induces metabolic and endocrine alterations which depend on the levels of testosterone exposure. PLoS One 2012;7:e37658. https://doi.org/10.1371/journal.pone.0037658
  15. Subbaramaiah K, Lin DT, Hart JC, Dannenberg AJ. Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2: evidence for involvement of activator protein-1 and CREB-binding protein/ p300. J Biol Chem 2001;276:12440-8. https://doi.org/10.1074/jbc.M007237200
  16. Lim H, Paria BC, Das SK, Dinchuk JE, Langenbach R, Trzaskos JM, et al. Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 1997;91:197-208. https://doi.org/10.1016/S0092-8674(00)80402-X
  17. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
  18. Kim HJ, Kim CH, Lee SM, Choe SA, Lee JY, Jee BC, et al. Outcomes of preimplantation genetic diagnosis using either zona drilling with acidified Tyrode's solution or partial zona dissection. Clin Exp Reprod Med 2012;39:118-24. https://doi.org/10.5653/cerm.2012.39.3.118
  19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001;25:402-8. https://doi.org/10.1006/meth.2001.1262
  20. Jansen E, Laven JS, Dommerholt HB, Polman J, van Rijt C, van den Hurk C, et al. Abnormal gene expression profiles in human ovaries from polycystic ovary syndrome patients. Mol Endocrinol 2004;18:3050-63. https://doi.org/10.1210/me.2004-0074
  21. Haouzi D, Assou S, Monzo C, Vincens C, Dechaud H, Hamamah S. Altered gene expression profile in cumulus cells of mature MII oocytes from patients with polycystic ovary syndrome. Hum Reprod 2012;27:3523-30. https://doi.org/10.1093/humrep/des325
  22. Zaree M, Shahnazi V, Fayezi S, Darabi M, Mehrzad-Sadaghiani M, Darabi M, et al. Expression levels of $PPAR{\gamma}$ and CYP-19 in polycystic ovarian syndrome primary granulosa cells: influence of ${\omega}$-3 fatty acid. Int J Fertil Steril 2015;9:197-204.
  23. Ramer R, Heinemann K, Merkord J, Rohde H, Salamon A, Linnebacher M, et al. COX-2 and $PPAR-{\gamma}$ confer cannabidiol-induced apoptosis of human lung cancer cells. Mol Cancer Ther 2013;12:69-82.
  24. Sander VA, Hapon MB, Sicaro L, Lombardi EP, Jahn GA, Motta AB. Alterations of folliculogenesis in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol 2011;124:58-64. https://doi.org/10.1016/j.jsbmb.2011.01.008
  25. Arif M, Thakur SC, Datta K. Disrupted hyaluronan binding protein 1 (HABP1) expression: one of the key mediator for ovarian dysfunction in polycystic ovary rat. Mol Cell Biochem 2015;398:233-44. https://doi.org/10.1007/s11010-014-2224-y
  26. Elkind-Hirsch KE. Thiazolidinediones for the therapeutic management of polycystic ovary syndrome: impact on metabolic and reproductive abnormalities. Treat Endocrinol 2006;5:171-87. https://doi.org/10.2165/00024677-200605030-00005
  27. Kim CH, Ahn JW, You RM, Kim SH, Chae HD, Kang BM. Pioglitazone treatment decreases follicular fluid levels of tumor necrosis factor-${\alpha}$ and interleukin-6 in patients with polycystic ovary syndrome. Clin Exp Reprod Med 2011;38:98-102. https://doi.org/10.5653/cerm.2011.38.2.98
  28. Amato G, Conte M, Mazziotti G, Lalli E, Vitolo G, Tucker AT, et al. Serum and follicular fluid cytokines in polycystic ovary syndrome during stimulated cycles. Obstet Gynecol 2003;101:1177-82.
  29. Samy N, Hashim M, Sayed M, Said M. Clinical significance of inflammatory markers in polycystic ovary syndrome: their relationship to insulin resistance and body mass index. Dis Markers 2009;26:163-70. https://doi.org/10.1155/2009/465203
  30. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 2000;49:497-505. https://doi.org/10.1007/s000110050622
  31. Chen Q, Sun X, Chen J, Cheng L, Wang J, Wang Y, et al. Direct rosiglitazone action on steroidogenesis and proinflammatory factor production in human granulosa-lutein cells. Reprod Biol Endocrinol 2009;7:147. https://doi.org/10.1186/1477-7827-7-147

Cited by

  1. DNA methylome profiling of granulosa cells reveals altered methylation in genes regulating vital ovarian functions in polycystic ovary syndrome vol.11, pp.None, 2017, https://doi.org/10.1186/s13148-019-0657-6
  2. Association of IL-17 and IL-23 follicular fluid concentrations and gene expression profile in cumulus cells from infertile women at risk for ovarian hyperstimulation syndrome vol.23, pp.4, 2020, https://doi.org/10.1080/14647273.2019.1566648